Eli Lilly and Co (LLY)

83.10
NYSE : Health Care
Prev Close 83.02
Day Low/High 82.50 / 83.22
52 Wk Low/High 64.18 / 86.72
Avg Volume 3.70M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 91.60B
EPS 2.60
P/E Ratio 35.78
Div & Yield 2.08 (2.50%)

Latest News

GOP Leaders Leave Behind Border Adjustment Tax

GOP Leaders Leave Behind Border Adjustment Tax

The Big Six GOP leaders, including Ryan and Mnuchin, are abandoning their plan for a border adjustment tax.

Alphabet Did Nothing to Push S&P 500 and Nasdaq to Fresh Records

Alphabet Did Nothing to Push S&P 500 and Nasdaq to Fresh Records

Wall Street at records.

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.

Amid Earnings Flood, Oil Rallies

OPEC expresses commitment to production cuts.

We're Gathering More Lilly

Post-earnings weakness presents a buying opportunity.

S&P 500 Hits All-Time High, Alphabet's Fall Pressures Nasdaq

S&P 500 Hits All-Time High, Alphabet's Fall Pressures Nasdaq

Stocks are mixed.

Eli Lilly's Quarter Was Strong, With a Top-and-Bottom-Line Beat

Despite some concerns, we expect to see strong earnings for the company moving forward as its new products continue to pay off.

Bulking Up a Pharma Position

We wanted to take advantage of short-term weakness in this stock.

Stock Futures Solidly Higher but Alphabet's Earnings Cause Concern

Stock Futures Solidly Higher but Alphabet's Earnings Cause Concern

Stock futures are higher.

Wall Street Preview: Tech Stocks and Oil in Focus

Wall Street Preview: Tech Stocks and Oil in Focus

Investors digest earnings from Alphabet Inc and Eli Lilly & Co.

The Dow Binges on Earnings

The Dow Binges on Earnings

Get ready for another heavy earnings slate

Earnings and Sentiment Boost Markets

Earnings and Sentiment Boost Markets

Investors return to risk markets

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens

U.S. stock futures turn higher on Tuesday following earnings from Alphabet.

European Stocks Called Higher as U.S. Dollar Rout Pauses

European Stocks Called Higher as U.S. Dollar Rout Pauses

Europe looks to rebound into earnings season

2 Animal Drugmakers Worth a Sniff

2 Animal Drugmakers Worth a Sniff

Aratana Therapeutics and Kindred Biosciences are promising drug developers in the pet space.

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.

Last Week's Portfolio Updates

A review of the changes we made in the portfolio.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

IBM CEO Ginni Rometty Rules Struggling Tech Giant, Aided by Entrenched Board Members

IBM CEO Ginni Rometty Rules Struggling Tech Giant, Aided by Entrenched Board Members

There are five over-tenured directors and four directors with whom CEO Ginni Rometty works with outside of the company, according to BoardEx.

Weekly Roundup

Earnings help boost markets as D.C. isn't counted on for much of anything. Portfolio action (it was a busy week) includes a new position and a downgrade.

Cutting Back on Snap-On

We'll sell over half our SNA position after digesting yesterday's results.

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

We're Downgrading Snap-On

Despite earnings beat, company is in a 'battleground.'

Exiting This Healthcare Name

We're selling our shares in Walgreens as our bullish thesis has lost its luster.

We're Initiating a Position in a Drug Maker

Bringing Eli Lilly out of the bullpen.

Doing Some Shuffling in the Bullpen

We're adding Nvidia, removing TMO and Six Flags, plus 2 updates.

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.

TheStreet Quant Rating: B+ (Buy)